ENTITY

Shire (SHPG US)

13
Analysis
Health CareJapan
SHIRE PLC is a global biotechnology group focused on serving people with rare diseases and other specialized conditions. The Company develops products across core therapeutic areas including hematology, immunology, neuroscience, ophthalmics, lysosomal storage disorders, gastrointestinal, internal medicine endocrine and hereditary angioedema, and in oncology.
more
25 Apr 2018 23:54

No Deal Is a Big Deal for Takeda

Takeda Pharmaceutical Co Ltd (4502 JP)'s revised April 24, 2018 proposal of £49 / share (~$206 / ADS), values Shire PLC (SHP LN) at ~$64b, its...

23 Apr 2018 13:49

The Week That Was in NorthAsia@Smartkarma: Itochu/FamilyMart, Samsung, Suruga, & Renesas

Below is the full list of Japan/Korea related reports published last week on Smartkarma.Itochu Tender For FamilyMartTravis Lundy explained the...

Logo
196 Views
Share
22 Apr 2018 20:49

Takeda Sweetens Offer for Shire: Deal – You Win! No-Deal – You Win Too!

Takeda Pharmaceutical Co Ltd (4502 JP)'s revised April 20, 2018 proposal of £47 / share (~$197.4 / ADS), valuing Shire PLC (SHP LN) at ~$60b, is...

bullishShire PLC
20 Apr 2018 10:51

Shire Remains Undervalued as Takeda Weighs Higher Bid and Allergan Enters the Picture

Shire PLC (SHP LN) has released details of recent negotiations with Takeda Pharmaceutical Co Ltd (4502 JP), detailing three proposed (and rejected)...

Logo
149 Views
Share
17 Apr 2018 20:55

Takeda + Shire - Monetizing Shire’s Neuroscience Division Could Be the Key

CEO Christopher Weber has always been vocal about his willingness to strike a multi-billion-dollar deal, if need be, to put in place Takeda’s...

x